PDF
(Download)
|
- Bergamot (Citrus bergamia, Rutaceae)
- Aromatherapy
- Mental Well-being
|
Date:
01-31-2018 | HC# 071754-585
|
Re: Effect of Bergamot Essential Oil on Mental Well-being
Han
X, Gibson J, Eggett DL, Parker TL. Bergamot (Citrus bergamia) essential oil inhalation improves positive
feelings in the waiting room of a mental health treatment center: A pilot study.
Phytother Res. 2017;31(5):812-816.
Aromatherapy
with essential oils is used to treat anxiety and depression. The major constituents
of essential oils thought to provide these benefits are linalool, limonene, and
pinene. Bergamot (Citrus bergamia, Rutaceae)
peel essential oil has a high content of limonene, linalool, and linalyl
acetate, and may be useful for improving overall mental health and anxiety. Hence,
the purpose of this randomized, placebo-controlled study was to evaluate the effect
of bergamot inhalation on mental well-being of subjects in the lobby of a
mental health treatment center waiting to receive treatment.
Women
and men (n = 57, aged 18-70 years) who were current companions or patients at the
mental health treatment center at The Green House Center for Growth and
Learning in Pleasant Grove, Utah, participated in the study. Included subjects could
communicate verbally and read and write in English, and were in the waiting
room during the study intervals. Excluded subjects were pregnant and/or
lactating, had no sense of smell, had known pre-existing sensitivities to
essential oils, or were judged by the staff of the treatment center as not good
candidates for the study.
This
pilot study was designed to mimic real-life usage of aromatherapy. There were 4
periods of treatment with bergamot and 4 periods of treatment with distilled water
(placebo). Depending on the week the subject came to the center, they were
exposed to either bergamot (dōTERRA International, LLC; Pleasant Grove, Utah) or
placebo aromatherapy in the waiting room. Four waterless diffusers were turned
on 15 min before the first subject arrived and were kept running at half speed
throughout the day. A comfortable and consistent aroma was maintained through
the day. Staff routinely checked each diffuser for fullness to ensure that each
subject received a similar strength and amount of vapor during the study
period. After sitting still in the waiting room for 15 minutes, subjects
completed the Positive and Negative Affect Schedule (PANAS), a standardized, validated
questionnaire which assesses momentary mental health and well-being. Adverse
events were recorded. To distract attention from the smell in the waiting room,
subjects were told that the study was to assess the waiting time's effect on
mental feelings.
Nearly
all of the subjects were female and Caucasian. Only 10 of 57 subjects were
patients of the treatment center; 47 subjects were companions. The
bergamot-treated group included all 10 patients of the treatment center. There
were a total of 45 subjects in the bergamot group and 12 subjects in the
control group. The bergamot group had higher PANAS scores than the control
group; however, there were no statistically significant differences between
treatment groups. Subjects in the bergamot group had a 48.8% higher score of
feeling "proud" and 43.4% higher score of feeling "active"
compared with the control group. However, the bergamot group had a 60% increase
of feeling "nervous" compared with the control group. There were no
adverse events reported.
The
authors conclude that "bergamot essential oil aromatherapy can be an
effective adjunct treatment to improve individuals' mental health and
well-being." However, this conclusion overstates the study data, as there
were no statistically significant differences between the groups and the
placebo group was very small. Additional study limitations include (1) baseline
PANAS was not measured, (2) the small control group prevented sufficient
statistical power to make definite conclusions, (3) only 10 subjects who were
being treated for mental health issues were included compared with 47
companions, and (4) the analysis combined data from the subjects with mental
health issues and their companions; bergamot may affect these 2 subpopulations
differently. The authors acknowledge that this is a pilot study.
The
study was sponsored by dōTERRA International, LLC, the manufacturer of the
bergamot essential oil. Two of the authors (Han and Parker) are employees of
dōTERRA International, LLC; another author (Eggett) is a consultant for the
company.
—Heather S. Oliff,
PhD
|